|Bid||46.00 x 800|
|Ask||49.73 x 900|
|Day's Range||48.06 - 49.77|
|52 Week Range||16.16 - 73.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.07|
Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.
Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would take profits in Crispr Therapeutics AG (NASDAQ: CRSP ). Enable Midstream Partners LP (NYSE: ENBL ) pays a good dividend, said ...
-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD-- Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018-- Preclinical Studies for CTX110 ...
The gene-editing technology called CRISPR has worked such wonders in laboratories that Wall Street values the technique’s three pioneers at a collective $5 billion, even though nobody’s tested the stuff in people yet. A shudder recently ran through the stocks—Crispr Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA)—after a few scientific studies raised concerns that gene-editing therapy might have serious side effects. If you don’t need to put CRISPR in humans, then side effects are not an issue.
The stock prices of gene-editing companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) saw a sharp correction in July. These companies are focused on clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology, and have fallen on concerns stemming from a recently published study.
How Intellia Therapeutics quickly became one of the top gene-editing biotech stocks on the market.
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial ...
These companies are reeling from last week's study showing potentially negative effects from their gene-engineering tools.
LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Lined up for scanning this morning are the following equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), CorMedix Inc. (NYSE AMER: CRMD), CRISPR Therapeutics AG (NASDAQ: CRSP), and Endocyte Inc. (NASDAQ: ECYT).
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / U.S. markets closed mostly lower on Monday, as upbeat economic data and the latest batch of corporate earnings failed to encourage investors. The Dow Jones Industrial ...
Shares of companies developing therapies using the gene-editing technology Crispr declined Monday following the publication of research suggesting Crispr could cause far more extensive DNA damage than previously thought, leading to potentially harmful health effects for patients. The study, published in the journal Nature Biotechnology, said the changes were often at places far away from the intentional edit, and so went undetected in previous studies, which typically observed smaller sections of genetic material. The latest paper adds to a growing body of research highlighting obstacles in developing the gene-editing technology, which has generated public interest and huge investment as a method that could potentially treat intractable genetic diseases.
Crispr Therapeutics (NASDAQ:CRSP) is down on Monday after an article in today’s issue of Nature (one of the most-trusted, well-known scientific journals) raised concerns about Crispr’s gene-editing technology. As of this writing, Crispr stock is down 7.9%. Crispr is a revolutionary gene-editing technology that has been widely embraced by the scientific community.
Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells. The findings, published in the journal Nature Biotechnology on Monday, have safety implications for gene therapies that are being developed using CRISPR/Cas9 - a type of molecular scissor technology that can be used to edit DNA. "We found that changes in the DNA have been seriously underestimated before now," said Allan Bradley, a professor at Britain's Wellcome Sanger Institute who co-led the research published on Monday.
This biotech has risen to the top of the CRISPR-Cas9 gene editing world. Here's how CRISPR Therapeutics did it.
MARKET PULSE Shares of companies developing CRISPR gene-editing therapies dropped in Monday morning trade after a study found that the technique can damage DNA. The research, published in the peer-reviewed journal Nature Biotechology, is just the latest questioning whether the technique brings more benefit than harms to patients, with a report in June raising the possibility that edited cells could cause cancer.
Investors are bidding up shares as the first drug candidates using the gene-editing technology inch closer to the clinic.
Investors began paying closer attention to the results from two studies suggesting a link between certain gene-editing tools and cancer.